We are live on ! Find out more
STSA

Satsuma Pharmaceuticals, Inc. Common Stock

Delisted

STSA was delisted on the 7th of June, 2023.

36 hedge funds and large institutions have $296M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

67% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 9

13% more funds holding

Funds holding: 3236 (+4)

12% more capital invested

Capital invested by funds: $264M → $296M (+$32.6M)

Holders
36
Holders Change
+4
Holders Change %
+12.5%
% of All Funds
0.79%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
6
Increased
15
Reduced
9
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of America
26
Bank of America
North Carolina
$79K +$67.6K +2,978 +425%
Wells Fargo
27
Wells Fargo
California
$70K +$65.4K +2,881 +805%
AIG
28
American International Group
New York
$57K -$2.81K -124 -4%
Victory Capital Management
29
Victory Capital Management
Texas
$46K +$49.1K +2,162 New
Deutsche Bank
30
Deutsche Bank
Germany
$36K +$4.43K +195 +13%
Citigroup
31
Citigroup
New York
$27K +$8.4K +370 +42%
SO
32
STRS Ohio
Ohio
$23K
Legal & General Group
33
Legal & General Group
United Kingdom
$11K -$8.29K -365 -40%
AIP
34
Ameritas Investment Partners
Nebraska
$8K
UBS Group
35
UBS Group
Switzerland
$6K -$124K -5,449 -95%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$6K +$454 +20 +7%
ZP
37
Zimmer Partners
New York
-$1.97M -100,000 Closed
Bank of Montreal
38
Bank of Montreal
Ontario, Canada
-$11K -559 Closed

STSA Hedge Fund Activity: Q1 2020 in Review

36 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q1 2020, worth a combined $296M — up 12% from $264M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new STSA positions and 2 closed out — a net gain of 4 holders — while 15 added to existing stakes and 9 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $12.7M. The largest seller was Wellington Management Group, cutting an estimated $5.94M.

  • 36 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q1 2020, up from 32 in Q4 2019.
  • Funds reported $296M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q1 2020, up 12% quarter-over-quarter.
  • 6 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +4 holders.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Eventide Asset Management, an estimated $12.7M added.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Wellington Management Group, an estimated $5.94M sold.

Based on aggregated 13F filings for Q1 2020.